



Proteomics International
LABORATORIES LTD

ASX Release
13 August 2026

ASX code: PIQ

Proteomics International secures Australian patent notice of acceptance for endometriosis innovative diagnostic test

- IP Australia has provided a notice of acceptance for a patent protecting the PromarkerEndo proprietary blood test for the diagnosis of endometriosis
- Major milestone with patent granted in PIQs local healthcare market
- The patent supports commercialisation efforts and underpins the commercialisation pathway, enabling future partnerships and licensing opportunities.
- Published clinical data has demonstrated the patented blood test has high accuracy for diagnosing endometriosis, including in the early stages of the disease
- Patent protection for the PromarkerEndo technology has now advanced in major jurisdictions including Japan, the United States and Australia
- Global need - endometriosis affects one in nine women and currently diagnosis typically takes an average of 7 years

Proteomics International Laboratories Ltd (Proteomics International; the Company; ASX: PIQ), a pioneer in precision diagnostics, is pleased to announce that the IP Australia provided a notice of acceptance for the Company's patent application covering PromarkerEndo, the proprietary diagnostic blood test for endometriosis.

The new patent provides intellectual property protection in the Australia for the Company's novel diagnostic test used for the diagnosis and treatment guidance of endometriosis. The patent strengthens Proteomics International's intellectual property portfolio and represents a major milestone towards securing granted patent protection in healthcare markets.

The patent covers methods of diagnosing endometriosis using specific protein biomarkers measured in blood samples and using the results to guide treatment selection. The patent protection is expected to extend until March 2041, subject to grant and maintenance requirements.

Proteomics International CEO and Managing Director Mr David Morris said, "The acceptance of this patent is another major achievement and further validation of the novelty and commercial potential of PromarkerEndo. Securing patent protection in our home jurisdiction is another critical step in our global commercialisation strategy."

Australia presents a significant market opportunity and is key to the commercialisation plans for the test, with increasing demand for innovative non-invasive diagnostic technologies that improve patient outcomes and reduce healthcare costs.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com

The patented technology is a core component of the Company's latest diagnostic test, which has demonstrated high accuracy in published clinical studies for detecting endometriosis, including the early stages of the disease [ASX: 30 December 2024, 26 May 2025]. The test aims to address a major unmet need in the timely and accurate diagnosis of endometriosis, improving patient outcomes and reducing healthcare costs.

Proteomics International is pursuing patent protection for the PromarkerEndo technology in multiple key jurisdictions, including Canada, China, Europe, India, Singapore and South Korea. The Company has already secured granted patent protection in Japan, the United States and now in Australia.

Authorised by the Chairman of Proteomics International Laboratories Ltd (ASX: PIQ).

ENDS

About Promarker®Endo

Proteomics International's diagnostics development is made possible by the Company's proprietary biomarker discovery platform called Promarker®, which searches for protein 'fingerprints' in a sample. This disruptive technology can identify proteins that distinguish between people who have a disease and people who do not, using only a blood test. It is a powerful alternative to genetic testing. PromarkerEndo is a diagnostic blood test for endometriosis, which could provide early screening to rule in or out the need for invasive surgery for women presenting with symptoms of endometriosis. Endometriosis is a common and painful condition that affects one in nine women and girls, occurring when tissue similar to the lining of the uterus grows in other parts of the body where it does not belong. The current way to test for the condition is a surgical laparoscopy, with diagnosis taking an average of 7 years.

About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

For further information please contact:

Dr James Williams
Chairman
Proteomics International Laboratories Ltd
T: +61 8 9389 1992
E: enquiries@proteomicsinternational.com

Mr David Morris
CEO & Managing Director
Proteomics International Laboratories Ltd
+61 8 9389 1992
E: enquiries@proteomicsinternational.com

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com